Summary: Researchers discovered that inhibiting a specific enzyme, USP30, in a mouse model protects dopamine-producing neurons, which are typically lost as the disease progresses.
This groundbreaking finding suggests a new therapeutic avenue that could slow or even prevent Parkinson’s progression.
The study involved both genetic and pharmacological methods to demonstrate the protective effects of USP30 inhibition on neuronal health and disease symptoms.
Key Facts:
The study showed that inhibiting the USP30 enzyme protected dopamine-producing neurons in a Parkinson’s mouse model.
Researchers used both genetic ‘knockout’ models and a proprietary molecule to block USP30, leading to increased clearance of damaged mitochondria.
These findings offer new hope for developing treatments that could potentially modify the course of Parkinson’s disease.
Written by
PDWarrior1900
To view profiles and participate in discussions please or .
They used the a53t mouse model - which shows they are serious about getting valid results. Crippled partly digested Mitochondria are a feature of Lewy bodies. This treatment cleans that up.
Thanks for posting this PDWarrior1900. Would anyone know whether this approach of inhibiting the USP30 enzyme, could hold any potential for a mouse 😉 .....or human with the PARK2/ PRKN genetic mutation variant of PD ?
The identity of S3 is 15-oxospiramilactone, a small compound (molecular weight of 330 Da) derived from diterpenoids. Diterpenoids are atisine-type natural products obtained from the complex of Spiraea japonica, a Chinese medicine widespread in Yunnan Province of China [10]. It has been reported that S3 could act as a covalent inhibitor with a cysteine residue of the protein forming an adduct with the N-cyano group to block the deubiquitinases activity of USP30. Moreover, S3 may induce the non-degradative ubiquitination of mitofusin (Mfn), which promotes mitochondrial fusion in mouse embryonic fibroblasts [11]. However, little is known about the role of S3 in RGCs under stressful conditions. Thus, the purpose of the present study was to address whether the small natural molecule S3 could protect RGCs and its mechanism involved in regulating mitochondrial quality control under NMDA-induced excitotoxicity.
So there might be some available supplements if you are keen to target USP30 inhibition
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Parkinson's Disease: emerging treatment target, the NLRP inflammasome. 
Methylphenidate for \"Parkinson's\"
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial
small study, but researchers report evidence of picornavirus antigen in 7 of 9 Parkinsons postmortem samples of midbrain
